Synapse - Nikoletta Lendvai

Results (106)

Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, Anti-CD38 Mab) in relapsed/refractory multiple myeloma (RRMM)

Meeting Abstract

Vij, R.; Martin, T.; Richter, J.; Cole, C.; Atanackovic, D.; Zonder, J.; Kaufman, J.; Mikhael, J.; Bensinger, W.; Dimopoulos, M.; more...
Haematologica (2016)

Fulltext@MSK | Save

A phase IB dose-escalation trial of isatuximab (SAR650984, anti-CD38 MAB) plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM): Interim results from 2 new dose cohorts

Meeting Abstract

Lendvai, N.; Vij, R.; Martin, T. G.; Baz, R.; Campana, F.; Mazuir, F.; Charpentier, E.; Benson, D. M.
Haematologica (2016)

Fulltext@MSK | Save

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma

Journal Article

Lendvai, N.; Yee, A. J.; Tsakos, I.; Alexander, A.; Devlin, S. M.; Hassoun, H.; Korde, N.; Lesokhin, A. M.; Landau, H.; Mailankody, S.; more...
Blood (2016)

Fulltext@MSK | Save

Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice

Journal Article

Jurczyszyn, A.; Grzasko, N.; Gozzetti, A.; Czepiel, J.; Cerase, A.; Hungria, V.; Crusoe, E.; Silva Dias, A. L. M.; Vij, R.; Fiala, M. A.; more...
American Journal of Hematology (2016)

Fulltext@MSK | Save

Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: Efficacy and cost analysis study

Journal Article

Afifi, S.; Adel, N. G.; Devlin, S.; Duck, E.; Vanak, J.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A.; Korde, N.; more...
Bone Marrow Transplantation (2016)

Fulltext@MSK | Save

A response adapted approach to induction treatment in patients with multiple myeloma undergoing autologous stem cell transplantation

Meeting Abstract

Shah, G. L.; Weltz, J.; Zhou, Q.; Devlin, S. M.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A. M.; Korde, N.; Koehne, G.; more...
Biology of Blood and Marrow Transplantation (2016)

Fulltext@MSK | Save

CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma

Journal Article

Smith, E.; Devlin, S. M.; Kosuri, S.; Orlando, E.; Landau, H.; Lesokhin, A. M.; Chung, D. J.; Hassoun, H.; Lendvai, N.; Landgren, O.; more...
Biology of Blood and Marrow Transplantation (2016)

Fulltext@MSK | Save

Strong MAGE-A3-specific humoral and cellular immune responses in multiple myeloma patients receiving MAGE-A3 protein immunotherapy and peripheral blood lymphocyte reconstitution

Meeting Abstract

Gnjatic, S.; Nataraj, S.; Imai, N.; Jungbluth, A. A.; Pan, L.; Venhaus, R.; Fellague-Chebra, R.; Gruselle, O.; Cohen, A.; Lendvai, N.; more...
Cancer Research (2015)

Fulltext@MSK | Save

Autologous hematopoietic stem cell transplantation overcomes primary refractory disease in multiple myeloma patients treated with novel agents

Meeting Abstract

Shah, G. L.; Hsu, M.; Devlin, S.; Chung, D. J.; Hassoun, H.; Koehne, G.; Korde, N. S.; Lendvai, N.; Lesokhin, A. M.; Landgren, O.; more...
Blood (2015)

Fulltext@MSK | Save

Biomarkers of cardiotoxicity among multiple myeloma patients subsequently treated with proteasome inhibitor therapy

Meeting Abstract

Lendvai, N.; Devlin, S.; Patel, M.; Knapp, K. M.; Ekman, D.; Grundberg, I.; Chung, D. J.; Hassoun, H.; Koehne, G.; Lesokhin, A. M.; more...
Blood (2015)

Fulltext@MSK | Save